Appeal 2007-2254
Application 10/383,115
wherein R1 is H, CH3 or OH and R2 is H or OH, or R1 and R2 taken together
are =CH2, R3 and R4 are H or OH and R5 is H, CI or N(CH3)2, in an amount
effective to inhibit or reduce amyloid plaque formation
2. REFERENCES
The Examiner relies on the following references:
Amin U.S. 5,919,775 Jul. 6, 1999
Andréa C. LeBlanc et al., Processing of Amyloid Precursor Protein in
Human Primary Neuron and Astrocyte Cultures, J. of Neurochemistry 1183-
1190 (1997) (“LeBlanc”).
Juha Yrjänheikki et al., Tetracyclines inhibit microglial activation and are
neuroprotective in global brain ischemia, 95 Proc. Natl. Acad. Sci. USA
15769-15774 (December 1998) (“Yrjänheikki”).
3. OBVIOUSNESS
Claims 1-3, 7, 9, 14, 15, 17, 20, 21, 30, 31, 47, and 48 stand rejected
under 35 U.S.C. § 103 as obvious over Amin and Yrjanheikki in view of
LeBlanc.1 The Examiner relies on Amin for teaching “the administration of
tetracycline compounds to treat various inflammatory conditions
characterized by nitric oxide production,” including Alzheimer’s disease
(Answer 4). The Examiner argues that the “tetracycline compounds
contemplated are disclosed in column 3 and . . . [include minocycline and
doxycycline,]” and that “[o]ptimal dosages are disclosed in column 8,
lines 59-66, which overlap with those recited in instant claims 14 and 15”
1 The Examiner relies on Yrjänheikki and LeBlanc for teaching limitations
of claims other than claim 1. However, because Appellant has not
separately argued the claims, we need not discuss these references.
3
Page: Previous 1 2 3 4 5 6 7 8 9 Next
Last modified: September 9, 2013